Name: Ye,Dingwei

  Professor and Chairman of the Department of Urology,
Director of the Multidisciplinary Team Approach for Genitourologic Malignancies,
VP of the Fudan University Shanghai Cancer Center,
President-elected of the Chinese Society of Urology Oncology,
President of Shanghai Anticancer Society,
Member of NCCN Asia Consensus for Bladder Cancer, Kidney Cancer and Prostate Cancer,
VP of Asia-Pacific Cryosurgery Society,
VP of Shanghai Urologic Association,
Education & Professional Experience   2007.10―Present: Vice President of Fudan University Cancer Hospital
2002.05―Present: Professor and Director of the Department of Urology ,Fudan University Cancer Hospital.[Dean and Archiater/ Professor & Supervisor of PhD]
1997.09―2000.07, PhD, Major: Urology, Second Military Medical University.
1996.09―1998.12: Post-Doc and Visiting Scientist in MD Anderson Cancer Center.
1990.09―1993.07, MS, Major: Urology, Second Military Medical University.
1986.07―2002.05: Department of Urology, Shanghai Changhai Hospital.[ Resident/ Attending & Lecturer/ Associate Archiater/ Associate Professor & Supervisor of Master]
1980.09―1986.07,BS, Major: Military Medicine, Second Military Medical University.
Specialty   Prostate cancer, Bladder cancer, kidney cancer, Penile cancer, testis cancer
Research   Prostate cancer,Bladder cancer ,kidney cancer,Penile cancer
Publication   1.Shi GH,Ye DW,Yao XD,Zhang SL, Dai B,Zhang HL,Shen YJ,Zhu Y,Zhu YP,Xiao WJ,Ma CG Involvement of microRNA-21 in mediating chemoresistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin. 2010 6;31(7):867-73 (Corresponding author)
2.Qing XJ,Ma CG,Ye DW,Yao XD,Zhang SL,Dai B,Zhang HL,Shen YJ,Zhu Y,Zhu YP,Shi GH,Xiao WJ,Lin GW,Swanson GP.Tumor Cytoreduction results in better response to androgen ablation-a preliminary report of palliative Transurethral Resection of the Prostate in metastatic. Urol Oncol. 2010 May 5. [Epub ahead of print] (Corresponding author)
3.Zhang HL,Yang LF,Zhu Y,Yao XD,Zhang SL,Dai B,Zhu YP,Shen YJ,Shi GH,Ye DW.Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel based chemotherapy. Prostate. 2010 Sep 14. [Epub ahead of print] (Corresponding author)
4.Dai B, Kong YY, Ye DW, Ma CG, Zhou X, Yao XD. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics. BJU Int. 2009, 104(7): 1009-1016. (Corresponding author)
5.Zhu YP, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ, Zhu Y, Shi GH. Prevalence of incidental prostate cancer in patients undergoing radical cystoprostatectomy: data from China and other Asian countries Asian J Androl. 2009 Jan; 11(1): 104-8. (Corresponding author)
6.Zhang HL, Ye D, Yao X, Dai B, Zhang S, Shen Y, Zhu Y, Mao H. Role of KIT expressionin the prognosis of clear cell renal cell carcinomas in Chinese patients. J CancerRes Clin Oncol. 2009 Feb;135(2):249-53. (Corresponding author)
7.Zhang HL,Ye DW, Yao X, Dai B, Zhang S, Shen Y, Zhu Y, et al Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: Results from a multicenter study. BMC Cancer 2009,21(8):249 (Corresponding author)
8.Zhu Y, Zhang SL, Ye DW, Yao XD, Dai B, Zhang HL, Shen YJ, Zhu YP, Shi GH, Ma CG. Prospectively packaged ilioinguinal lymphadenectomy for penile cancer: the disseminative pattern of lymph node metastasis. J Urol 2009,181(5): 2103-2108(Corresponding author)
9.Zhu Y, Zhang SL, Ye DW, Yao XD, Dai B, Zhang HL, Shen YJ, Zhu YP,Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget's disease. Brit J Ddermatol 2009,161(3):577-582(Corresponding author)
10.LingGW,YaoXD,YeDW, Prostate specific antigen half life, as a new predictor of progression-free survival and overall survival for Chinese prostate cancer patientsAsian J Androl 2009,11(4): 443-50(Corresponding author)
11.Dai B, Ye DW, Kong YY, Shen YJ, Wang BH. Individualized prostate biopsy strategy for Chinese patients with different prostate-specific antigen levels. Asian J Androl, 2008, 10(2): 325-31. (Corresponding author)
12.Dai B, Kong YY, Ye DW, Ma CG, Zhou XY, Yao XD. Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy. Asian J Androl. 2008 (5): 01-9. (Corresponding author)
13.Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ. The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. J Urol. 2008 Nov;180(5):2019-23. (Corresponding author)
14.Zhu Y, Zhang SL, Ye DW, Yao XD, Jiang ZX, Zhou XY. Predicting pelvic lymph node metastases in penile cancer patients: a comparison of computed tomography, Cloquet's node, and disease burden of inguinal lymph nodes. Onkologie. 2008 Feb;31(1-2):37-41. (Corresponding author)
15.Shen YJ, Ye DW, Yao XD, Trink B, Zhou XY, Zhang SL, Dai B, Zhang HL, Zhu Y, Guo Z, Wu G, Nagpal J. Overexpression of CDC91L1 (PIG-U) in bladder urothelial cell carcinoma: correlation with clinical variables and prognostic significance. BJU Int. 2008 Jan; 101(1): 113-9. (Corresponding author)
16.Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W. Docetaxel plus Prednisone versus Mitoxantrone plus Prednisone for Metastatic Hormone-Refractory Prostate Cancer in Chinese Patients: Experience of a Single Center. Urol Int 2007;79:307-311. (Corresponding author)
17.Zhu Y, Ye DW, Chen ZW, Zhang SL, Qin XJ. Frozen section-guided wide local excision in the treatment of penoscrotal extramammary Paget's disease. BJU Int, 2007, 100:1282-7. (Corresponding author)
18.Zhu Y, Zhou XY, Yao XD, Dai B, Ye DW. The prognostic significance of p53, Ki-67, epithelial cadherin and matrix metalloproteinase-9 in penile squamous cell carcinoma treated with surgery. BJU Int, 2007, 100:204-8. (Corresponding author)
19.Dai B, Ye DW, Kong YY, Yao XD, Zhang HL, Shen YJ. Predicting Regional Lymph Node Metastasis in Chinese Patients With Penile Squamous Cell Carcinoma: The Role of Histopathological Classification, Tumor Stage and Depth of Invasion. J Urol, 2006, 176: 1431-1435. (Corresponding author)
20.Ye DW, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER mAb2 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 1999;18:731
21.Ye DW, Mendelsohn J, Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res, 1999, 5:2171-2177
22.Ye DW, Li H, Qian S, Sun Y, Zheng J, Ma Y. bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection. J Urol 1998; 160: 202.
23.Ye DW, Zheng J, Qian SX, Ma Y, Zheng X, Li D, Gu S. .P53 gene mutation in Chinese human testicular seminoma. J Urol 1993;150:884.
24.Ye DW, Zheng JF, Qian SX. Expression of p53 product in Chinese human bladder carcinoma. Urol Res 1993;21:223.
25.Ye DW, Zheng JF, Qian SX.Correlation between the expression of oncogene ras and c-erbB-2 and the biological behavior of bladder tumor. Urol Res 1993;21:39.

Awards   2009 “Plan of Academic Pacesetter in Leading Discipline”[Rank A] Science and Technology Commission of Shanghai Municipality
2006&2007 “Excellent Supervisor of PhD” Fudan University Cancer Hospital &“Academic Leader project” Chinese Urological Association [both awarded twice]
2005 “Excellent Supervisor of Master” Fudan University Cancer Hospital
2003~2005 “Advanced Worker of Health System” Public Health Bureau of Shanghai Municipality

Optimization and application of treatment strategies for Chinese prostate cancer patients,Shanghai Science and Technology Progress Award, First Prize
Investigation of optimizing personalized treatment strategies for advanced prostate cancer,University 's Science and Technology Progress Award, First Prize
Translational studies of prostate cancer, Science and Technology Award of Chinese Anti-Cancer Association, Second Prize

Exploration for mechanism of androgen independent transition and metastasis in prostate cancer and personalized comprehensive treatment, Chinese Medical Science and Technology Progress Award, Second Prize

Exploration for mechanism of androgen independent transition and metastasis in prostate cancer and personalized comprehensive treatment, Shanghai Medical Science and Technology Award, Second Prize

Endos Medical Science and Technology Award, Outstanding Achievement Award

Innovation and application of diagnosis and treatment system for prostate cancer, National Science and Technology Progress Award, First Prize, Third Responsibility

Research and Application of new diagnosis and treatment strategies in penile cancer,Shanghai Science and Technology Progress Award, First Prize
The establishment of penile cancer systematic prediction model and individualized diagnosis and treatment strategies,Science and Technology Award of Shanghai Medical Association, First Prize

Research and Application of new diagnosis and treatment strategies in penile cancer,Science and Technology Progress Award of Education Ministry, Second Prize
Out-patient Schedule  

VIP Clinic -Monday morning
Specialist Clinic -Wednesday morning